Understanding the polypharmacology of Proteinase-activated receptor (PAR) pepducins and investigating their biophysical association using mass spectrometry imaging (MSI) technologies
Background: Conventional antiplatelet therapies consist of drugs that target surface proteins called G protein-coupled receptors (GPCRs), Competitive antagonists, such as Vorapaxar, which inhibits proteinase-activated receptor-1 (PAR1), has been associated with severe bleeding [1]. High affinity, co...
Saved in:
Published in | Proceedings for Annual Meeting of The Japanese Pharmacological Society Vol. WCP2018; p. OR26-5 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Japanese Pharmacological Society
2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!